Trigonelline is an NAD precursor that improves muscle function during ageing and is reduced in human sarcopenia

Grants

Funding Acknowledgements

The clinical data are derived from a collaborative project by the MEMOSA Study Group including C. Cooper, H. Patel, E. Dennison and T. Forrester, and involving the Nestle Institute of Health Sciences and the EpiGen Consortium, an international alliance of researchers at the Universities of Auckland, New Zealand, and Southampton (Centre for Biological Sciences, Medical Research Council Lifecourse Epidemiology Centre), UK, the Singapore Institute for Clinical Sciences of the Agency for Science, Technology and Research (A*STAR), National University of Singapore and UWI Solutions for Developing Countries, University of the West Indies. We thank the study participants for making this work possible and staff at our institutions for assistance in participant recruitment, performing the measurements and for project management. We also thank G. Jacot and M. Lys (Nestle Research) for support with sourcing trigonelline and for project management, J.-P. Godin (Nestle Research) for support with metabolomics design and interpretation, S. Karaz (Nestle Research) for support with the in vivo experiments, S. Cheung (Biological Optical Microscopy Platform at The University of Melbourne) for assistance with the histological analyses, A. Hermant (Nestle Research) for support with the mitochondrial respiration assays, S. Ancel (Nestle Research) for providing the primary mouse muscle stem cells and A. Tammaro (Department of Pathology, Amsterdam University Medical Centre) for providing the IM-PTEC cells. The project was funded by Nestle Research, Nestle Health Sciences and direct funding to the senior authors. V.S. is supported by the National University Health System (NUHS) Internal Grant Funding under a National University of Singapore Start-up grant no. NUHSRO/2022/047/Startup/11. M.E.M. and M.V.M. are supported by the Mitchell Cancer Institute start-up funds and grant no. R21 AT009908 from the National Center for Complementary and Integrative Health, the National Institutes of Health (NIH), Health and Human Services. K.M.G. is supported by the UK Medical Research Council (MC_UU_12011/4), the National Institute for Health and Care Research (NIHR) (Senior Investigator (NF-SI-0515-10042)) and the NIHR Southampton Biomedical Research Centre (NIHR203319), the European Union (Erasmus+ Programme ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP), the British Heart Foundation (RG/15/17/3174, SP/F/21/150013), the U.S. National Institute On Aging of the NIH (award no. U24AG047867) and the UK Economic and Social Research Council and Biotechnology and Biological Sciences Research Council (award no. ES/M00919X/1). J.T.T., E.D. and A.M.E. were supported by the Novo Nordisk Foundation Centre for Basic Metabolic Research (Centre for Basic Metabolic Research (CBMR)). CBMR is an independent research centre at the University of Copenhagen, which is partially funded by an unrestricted donation from the Novo Nordisk Foundation (NNF18CC0034900). T.N. is supported by the Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) (21K11593 to K.Y. and 22H03505) and AMED-PRIME (grant no. 23gm6710007h0002). C.C. is supported by funding from the European Union's Horizon Europe research and innovation programme (MSCA-DN-NADIS; grant no. 101073251).